
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Advertising (2) Apply Advertising filter
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (2) Apply Biologicals filter
- Remove Blood and blood components filter Blood and blood components (0)
- Remove Complementary medicines filter Complementary medicines (7)
- Remove Cosmetics filter Cosmetics (0)
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Listed medicines (2) Apply Listed medicines filter
- Remove Manufacturing filter Manufacturing (0)
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Remove Medical devices safety filter Medical devices safety (1)
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- OTC medicines (12) Apply OTC medicines filter
- Other therapeutic goods (1) Apply Other therapeutic goods filter
- Prescription medicines (5) Apply Prescription medicines filter
- Scheduling (55) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Remove Therapeutic goods regulation filter Therapeutic goods regulation (2)
- (-) Remove Cosmetics filter Cosmetics
- (-) Remove Therapeutic goods regulation filter Therapeutic goods regulation
- (-) Remove Manufacturing filter Manufacturing
- (-) Remove Blood and blood components filter Blood and blood components
- (-) Remove Medical devices safety filter Medical devices safety
- (-) Remove Complementary medicines filter Complementary medicines
Proposed update to the evidence guidelines for listed medicines
Closed on 1 April 2022
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Lidocaine (lignocaine)
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Sedating antihistamines
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Menthol
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Methyl salicylate
Closed on 18 May 2021
Proposal to remove redundant processes for entering certain formulation information into a therapeutic goods application
Closed on 24 February 2021
IMDRF consultation: Proposed update to document on Post-Market Clinical Follow-Up Studies
Closed on 11 December 2020
Proposed clarification that goods are therapeutic goods - goods containing folate substances in certain circumstances
Closed on 18 September 2019
Discontinuing pre-market evaluation of Herbal Component Names (HCNs)
Closed on 12 January 2018
Options for the future regulation of 'low risk' products
Closed on 12 May 2017